SCHEMBL4767263

SCHEMBL4767263

COc1ccc2ccccc2c1C1=CC=CO[C]1

nearest known ligand 0.57

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.57
MEN1 O00255 3/20 0.45
KMT2A Q03164 3/20 0.45
ALDH1A1 P00352 1/20 0.45
RAB9A P51151 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
NISCH Q9Y2I1 1/20 0.43
KDM4E B2RXH2 1/20 0.38
HPGD P15428 1/20 0.38
NQO1 P15559 1/20 0.37
GPR84 Q9NQS5 1/20 0.34
PKM P14618 1/20 0.33
ABCG2 Q9UNQ0 1/20 0.33
MTNR1A P48039 1/20 0.33
MTNR1B P49286 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4724055 0.85 ALOX5 (0.47) MAPTALDH1A1RAB9AKDM4EHPGD
SCHEMBL4767156 0.83 CNR1 (0.40) MAPTMEN1KMT2ACYP1A2CYP2C9
SCHEMBL998182 0.75 MAPT (1.00) MAPTMEN1KMT2AALDH1A1RAB9A
SCHEMBL29428410 0.75 MAPT (1.00) MAPTMEN1KMT2AALDH1A1RAB9A
SCHEMBL22534454 0.70 MAPT (0.88) MAPTMEN1KMT2AALDH1A1RAB9A
SCHEMBL31336201 0.70 MAPT (0.88) MAPTMEN1KMT2AALDH1A1RAB9A
SCHEMBL30719041 0.69 MAPT (0.78) MAPTMEN1KMT2AALDH1A1RAB9A
SCHEMBL619380 0.69 MAPT (0.78) MAPTMEN1KMT2AALDH1A1RAB9A
SCHEMBL5110113 0.69 MAPT (0.55) MAPTMEN1KMT2AALDH1A1RAB9A
SCHEMBL12880138 0.67 MAPT (0.75) MAPTMEN1KMT2AALDH1A1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080176857-A1 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors PFIZER INC. 2008-07-24 US disclosed
EP-1874780-A1 4-PIPERAZINYLTHIENO[2,3-D]PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS Pharmacia & Upjohn Company LLC (US) 2008-01-09 EP disclosed
WO-2006100591-A1 4-PIPERAZINNYLTHIENO [2,3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS PHARMACIA & UPJOHN COMPANY LLC (US) 2006-09-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176857-A1 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors TBXA2R, P2RY4, PF4 MAPT 4361/4885MEN1 4451/4885KMT2A 3345/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.